Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 3/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | CPB1 | P15086 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27514751 | 0.91 | SRD5A2 (0.50) | NPC1RAB9ASRD5A2MEN1KMT2A | |
| SCHEMBL5214996 | 0.91 | SRD5A2 (0.55) | NPC1RAB9ASRD5A2MEN1KMT2A | |
| SCHEMBL5218499 | 0.90 | SRD5A2 (0.58) | NPC1RAB9ASRD5A2MEN1KMT2A | |
| SCHEMBL25292565 | 0.86 | POLB (0.43) | NPC1RAB9ASRD5A2MEN1KMT2A | |
| SCHEMBL11716695 | 0.86 | MEN1 (0.62) | NPC1RAB9ASRD5A2MEN1KMT2A | |
| SCHEMBL21402759 | 0.86 | PLG (0.47) | NPC1RAB9ASRD5A2MEN1KMT2A | |
| SCHEMBL4040222 | 0.83 | MEN1 (0.47) | MEN1KMT2AHTR2AHTR2CHSD11B1 | |
| SCHEMBL11710930 | 0.79 | CYP2D6 (0.50) | SRD5A2MEN1KMT2ACYP2D6HTR2C | |
| SCHEMBL25251891 | 0.79 | POLB (0.41) | SRD5A2HSD11B1SMN1; SMN2POLB | |
| SCHEMBL21590150 | 0.78 | KMT2A (0.44) | MEN1KMT2AHSD11B1MGLLPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1215045-C | Stable salts of novel derivatives of 3, 3-diphenylpropylamines | SANOL ARZNEI SCHWARZ GMBH (DE) | 2005-08-17 | — | — | CN | claimed |
| CN-1390194-A | Stable salts of novel derivatives of 3, 3-diphenylpropylamines | SANOL ARZNEI SCHWARZ GMBH (DE) | 2003-01-08 | — | — | CN | claimed |
| CN-107428678-A | Method for preparing 2 [4 (cyclopropane carbonyl) phenyl] 2 methyl propionitrile | 赛诺菲-安万特德国有限公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-107428678-A | Method for preparing 2 [4 (cyclopropane carbonyl) phenyl] 2 methyl propionitrile | 赛诺菲-安万特德国有限公司 | 2017-12-01 | — | — | CN | disclosed |
| US-8273767-B2 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2406220-A1 | BIS AROMATIC COMPOUNDS FOR USE AS LTC4 SYNTHASE INHIBITORS | Biolipox AB (SE) | 2012-01-18 | — | — | EP | disclosed |
| US-20120004228-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | BIOLIPOX AB (SW) | 2012-01-05 | — | — | US | disclosed |
| US-7947711-B2 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110112193-A1 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | BIOLIPOX AB (SE) | 2011-05-12 | — | — | US | disclosed |
| US-20110098285-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-04-28 | — | — | US | disclosed |
| CN-102036952-A | Bis-aryl compounds for use as medicaments | BIOLIPOX AB | 2011-04-27 | — | — | CN | disclosed |
| US-20030153548-A1 | Histamine-3 receptor ligands for diabetic conditions | ABBOTT LABORATORIES | 2003-08-14 | — | — | US | disclosed |
| WO-2003059341-A1 | 1,3-DISUBSTITUTED AND 1,3,3,-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003059342-A1 | HISTAMINE-3 RECEPTOR LIGANDS FOR DIABETIC CONDITIONS | ABBOTT LABORATORIES (US) | 2003-07-24 | — | — | WO | disclosed |
| US-20030134835-A1 | Histamine-3 receptor ligands for diabetes conditions | ABBOTT LABORATORIES | 2003-07-17 | — | — | US | disclosed |
| EP-1301480-A1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6515013-B2 | For diseases or conditions caused by or exacerbated by histamine-3 receptor activity | ABBOTT LABORATORIES | 2003-02-04 | — | — | US | disclosed |
| US-20020137931-A1 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-09-26 | — | — | US | disclosed |
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-03-21 | — | — | US | disclosed |
| WO-2002006223-A1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137931-A1 | 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | NPC1 2137/4885RAB9A 1738/4885SRD5A2 3281/4885 |
| US-20020035103-A1 | 1,3-Disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications | HRH3, HRH4, HRH1 | NPC1 2137/4885RAB9A 1738/4885SRD5A2 3281/4885 |
| US-20110098285-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | HRH3, HRH4, HRH2 | NPC1 1427/4885RAB9A 1315/4885SRD5A2 2885/4885 |
| US-20110112193-A1 | BIS-ARYL COMPOUNDS FOR USE AS MEDICAMENTS | LTC4S, LTB4R2, LTB4R | NPC1 1850/4885RAB9A 3833/4885SRD5A2 899/4885 |
| US-20030153548-A1 | Histamine-3 receptor ligands for diabetic conditions | HRH4, HRH2, HRH3 | NPC1 3697/4885RAB9A 2934/4885SRD5A2 3450/4885 |
| US-20030134835-A1 | Histamine-3 receptor ligands for diabetes conditions | HRH4, HRH2, HRH3 | NPC1 3440/4885RAB9A 2929/4885SRD5A2 3316/4885 |
| US-20120004228-A1 | Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors | LTC4S, LTB4R2, LTB4R | NPC1 2560/4885RAB9A 3916/4885SRD5A2 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.